Akari Therapeutics (AKTX)
(Delayed Data from NSDQ)
$1.19 USD
0.00 (0.00%)
Updated Apr 25, 2024 03:56 PM ET
3-Hold of 5 3
F Value B Growth NA Momentum NA VGM
Income Statements
Fiscal Year end for Akari Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 17 | 23 | 17 | 18 | 17 |
Income After Depreciation & Amortization | -17 | -23 | -17 | -18 | -17 |
Non-Operating Income | 7 | 5 | 0 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -10 | -18 | -17 | -17 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | -18 | -17 | -17 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | -18 | -17 | -17 | -17 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -17 | -23 | -17 | -18 | -17 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -17 | -23 | -17 | -18 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 978.90 | 3.12 | 2.15 | 1.58 | 0.92 |
Diluted EPS Before Non-Recurring Items | -0.01 | -5.60 | -8.20 | -10.80 | -18.60 |
Diluted Net EPS (GAAP) | -2.05 | -5.60 | -8.20 | -20.00 | -20.00 |
Fiscal Year end for Akari Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |